Miller LE, et al. - In chronic rhinosinusitis (CRS) management, conservative treatment is frequently provided that includes a combination of topical and oral corticosteroids (OCSs). However, in the middle of the coronavirus disease 2019 (COVID-19) pandemic, providers may show reluctance to prescribing OCSs out of possible concern for an elevated risk of contracting COVID-19 or developing more severe COVID-19 symptoms. Researchers herein investigated if and how the use of OCSs is associated with the development of COVID-19 in patients with CRS. No statistically significant difference was observed in the rates of patients with a positive diagnosis of COVID-19 who underwent an OCS treatment regimen vs those who did not, both within 28 days and 14 days prior to the COVID-19 test. These findings may aid in counseling patients on risks of steroid use in CRS treatment during the COVID-19 pandemic given OCSs are often a major component of medical management of CRS.